Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues
- PMID: 7995947
Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues
Abstract
Human NK cells can be separated into two functionally distinct subpopulations based on the ability to rapidly respond to IL-2 by adherence to solid surfaces. To determine functions of the NK cell subsets in solid tumor tissues, adherent (A) and nonadherent (NA) NK cells were evaluated for their ability to infiltrate multicellular tumor spheroids in vitro, to kill carcinoma (CA) cell targets in these spheroids, and to mediate antitumor activity in vivo. A-NK cells were less cytolytic than NA-NK cells against CA targets in single cell suspensions or in monolayers. However, A-NK cells showed a significantly better ability than NA-NK cells to infiltrate tumor tissues and kill tumor cells in spheroids of human squamous cell CA of the head and neck or breast CA. Perilesional delivery of human A-NK cells and IL-2 resulted in regression of established human squamous cell carcinoma of the head and neck tumors growing subcutaneously in immunosuppressed nude mice. Similarly, in a xenograft model of human gastric CA metastatic to liver of nude mice, a single intrasplenic injection of A-NK cells in combination with i.p. infusions of IL-2 significantly reduced the number of established hepatic metastases (p < 0.007) and prolonged survival of the mice (p < 0.003). In contrast, NA-NK cells were ineffective in either of the in vivo xenograft tumor models. These findings demonstrate that A-NK cells represent a biologically unique and important subset of NK cells that, in contrast to the rest of NK cells, function as effector cells in solid tumor tissues and, consequently, have a great antitumor therapeutic potential.
Similar articles
-
Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.Clin Cancer Res. 1998 May;4(5):1135-45. Clin Cancer Res. 1998. PMID: 9607570
-
Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.J Immunol. 1992 Jul 1;149(1):340-9. J Immunol. 1992. PMID: 1535088
-
Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.Cancer Res. 1994 Jul 15;54(14):3808-16. Cancer Res. 1994. PMID: 8033100
-
The biology of human natural killer cells.Ann Ist Super Sanita. 1990;26(3-4):335-48. Ann Ist Super Sanita. 1990. PMID: 2091502 Review.
-
Effective immunotherapy with local low doses of interleukin-2.In Vivo. 1991 Nov-Dec;5(6):561-5. In Vivo. 1991. PMID: 1810439 Review.
Cited by
-
Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.Cancer Immunol Immunother. 1995 Jul;41(1):37-45. doi: 10.1007/BF01788958. Cancer Immunol Immunother. 1995. PMID: 7641218 Free PMC article.
-
Chronic inflammation in cancer development.Front Immunol. 2012 Jan 12;2:98. doi: 10.3389/fimmu.2011.00098. eCollection 2011. Front Immunol. 2012. PMID: 22566887 Free PMC article.
-
Present and Future of Allogeneic Natural Killer Cell Therapy.Front Immunol. 2015 Jun 3;6:286. doi: 10.3389/fimmu.2015.00286. eCollection 2015. Front Immunol. 2015. PMID: 26089823 Free PMC article. Review.
-
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.J Nutr. 2008 Jan;138(1):115-22. doi: 10.1093/jn/138.1.115. J Nutr. 2008. PMID: 18156413 Free PMC article.
-
Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes.Clin Exp Immunol. 2001 May;124(2):214-22. doi: 10.1046/j.1365-2249.2001.01550.x. Clin Exp Immunol. 2001. PMID: 11422197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical